Recently, another novel cis-activating mechanism has been revealed: binding to the chimeric HBV EnhI at the TERT promoter, ELF4 could achieve TERT activation in TERT HBV-integrated HCC (62). This evidence concerns the gene TERT and hepatocellular carcinoma.